Talk:Lansoprazole

Following information from DrugBank should be added: "Mechanism of Action. Lansoprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that do not exhibit anticholinergic or histamine H2-receptor antagonist properties, but rather suppress gastric acid secretion by specific inhibition of the (H+,K+)-ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the parietal cell, Lansoprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production. This effect is dose-related and leads to inhibition of both basal and stimulated gastric acid secretion irrespective of the stimulus.

Protein binding is approximately 97%

Biotransformation. Hepatic. Two metabolites have been identified in measurable quantities in plasma (the hydroxylated sulfinyl and sulfone derivatives of lansoprazole). These metabolites have very little or no antisecretory activity. Lansoprazole is thought to be transformed into two active species which inhibit acid secretion by (H+,K+)-ATPase within the parietal cell canaliculus, but are not present in the systemic circulation."

After getting a prescription for Prevacid, I was pleased to see that Wikipedia had a page, but was confronted with several unfamiliar terms. It made the most sense to make them links, so that I could read the other pages. I'm not completely happy with the Side Effects section - perhaps everything should be a link, even common terms like nausea.

In the course of making the changes, I found several possible misspellings:

• insommnia -> insomnia
• angiodema -> angioedema
• leucopoenia -> leukopenia
• leucocytosis -> leukocytosis
• athralgia -> arthralgia

http://www.wrongdiagnosis.com/medical-misspelling helped in some cases, but it is possible that I've confused two similar technical terms, since I have no medical training.

Also, bisacodyl and delavirdine are non-existant pages with links to them, so I'm reasonably sure they are spelled correctly. JohnWhitlock 19:15, 21 March 2006 (UTC)Reply

And now, they exist. Wikipedia works. JohnWhitlock 21:58, 10 April 2006 (UTC)Reply

This version of the information appears to be more complete than previous. Does it not? —Preceding unsigned comment added by 156.70.222.27 (talk • contribs)

It is, but that is not the point; much of the content you added seems to have been copied word for word from the lansoprazole prescribing information (evidence here). Linking to prescribing information is fine, but "citing" it verbatim is not. Some of the content present in PIs may also make the atricle too technical for the general reader, which runs contrary to the purpose of an encyclopedia, not to mention this proposal. Original content – in your own words – is more than welcome, but meanwhile, I have reverted your edit. Also, please remember to sign your comments and posts by typing four tildes (like this: ~~~~) before saving: it makes it easier to identify who said what and prevents confusion. Fvasconcellos 19:38, 15 September 2006 (UTC)Reply

I think information regarding the history of the drug and how it was developed should be added to this and all drugs on Wikipedia. This information should include the date it was first available to patients.

which is it? —Preceding unsigned comment added by 98.111.220.126 (talk) 01:46, 25 January 2011 (UTC)Reply

Is the relative price of the generic brand compared to prevacid really necessary? I've never seen this on any other drug related page and it just doesn't seem to fit at all. Wikipedia doesn't really seem the place to list relative prices. 96.30.140.164 (talk) 22:46, 10 March 2011 (UTC)Reply

Prevacid is OTC only now. It is very inexpensive and is the preferred PPI in cardio and Hypertension paitents to avoid fatal contradictions with prilosec. —Preceding unsigned comment added by 69.148.205.46 (talk) 14:39, 30 April 2011 (UTC)Reply

Long term use side effect: as noted by the FDA, Proton pump inhibitors cause a flux of Magnesium in the blood, therefore causing muscle contractions and spasms. Also long term use has been noted in intestinal blockages due to undigested food particles massing together. —Preceding unsigned comment added by 69.148.205.46 (talk) 14:37, 30 April 2011 (UTC)Reply

The 3D image should be deleted. It shows only one enantiomer of a racemic compound. Best regards, --Jü (talk) 16:51, 1 February 2012 (UTC)Reply

Does anyone know if lansoprazole specifically inhibits certain liver enzymes - as opposed to simply (I presume) partially saturating them as with 3A4 and 2C19? — Preceding unsigned comment added by Jimw338 (talk • contribs) 23:24, 7 August 2012 (UTC)Reply

Content that violates any copyrights will be deleted. Encyclopedic content must be verifiable. Work submitted to Wikipedia can be edited, used, and redistributed—by anyone—subject to certain terms and conditions. — Preceding unsigned comment added by 188.247.76.167 (talk) 16:56, 7 November 2013 (UTC)Reply

this article needs to be rewritten by someone with command in either north american english or british english

there are a bunch of incomplete sentences — Preceding unsigned comment added by 24.6.88.206 (talk) 02:05, 8 November 2013 (UTC)Reply

This content was added by Bcary in this dif which i reverted b/c it is based on primary sources that fail WP:MEDRS and was added back in the form in this dif] which i again reverted as it has the same problems:

Lansoprazole selectively interacts with tau neurofibrillary tangles: a biomarker of Alzheimer's disease.^[1] Lansoprazole itself does not efficiently cross the blood-brain barrier.^[2] However, derivatives of lansoprazole have been investigated as potential PET probes for measuring tau in vivo.^{[2] [3] [4] [5]}

References

1. ^ Rojo, LE; Alzate-Morales, J; Saavedra, IN; Davies, P; Maccioni, RB (2010). "Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer's disease". Journal of Alzheimer's disease : JAD. 19 (2): 573–89. PMID 20110603.
2. ^ ^{a b} Fawaz, MV; Brooks, AF; Rodnick, ME; Carpenter, GM; Shao, X; Desmond, TJ; Sherman, P; Quesada, CA; Hockley, BG; Kilbourn, MR; Albin, RL; Frey, KA; Scott, PJ (20 August 2014). "High affinity radiopharmaceuticals based upon lansoprazole for PET imaging of aggregated tau in Alzheimer's disease and progressive supranuclear palsy: synthesis, preclinical evaluation, and lead selection". ACS chemical neuroscience. 5 (8): 718–30. PMID 24896980.
3. ^ Shao, Xia; Carpenter, Garrett M.; Desmond, Timothy J.; Sherman, Phillip; Quesada, Carole A.; Fawaz, Maria; Brooks, Allen F.; Kilbourn, Michael R.; Albin, Roger L.; Frey, Kirk A.; Scott, Peter J. H. (8 November 2012). "Evaluation of 11C-Methyl Lansoprazole as a Radiopharmaceutical for PET Imaging of Tau Neurofibrillary Tangles". ACS Medicinal Chemistry Letters. 3 (11): 936–941. doi:10.1021/ml300216t.
4. ^ Wolf, Lauren (June 16, 2014). "Tracing Tau In The Alzheimer's Brain". No. 24. CAEN. American Chemical Society. Retrieved 16 May 2015.
5. ^ Villemagne, VL; Fodero-Tavoletti, MT; Masters, CL; Rowe, CC (January 2015). "Tau imaging: early progress and future directions". The Lancet. Neurology. 14 (1): 114–24. PMID 25496902.

PMID 20110603 and PMID 24896980 and the "Evaluation of 11C-Methyl article (PMID 24900410) are primary sources as defined in WP:MEDRS. The "Tracing Tau In The Alzheimer’s Brain" is a popular media article describing a primary source - also not OK per WP:MEDRS. The last source PMID 25496902 - is a good source by MEDRS. What that article says about is as follows: "Lansoprazole was selected as a potential tau PET tracer on the basis of its in-vitro binding affinity for PHF-tau. A series of lansoprazole derivatives, with subnanomolar binding affinity for tau fibrils, was radiolabelled with 11C,60 and more recently with 18F. A study of 11C-N-methyl lansoprazole in mice showed no entry of the tracer into the brain, but this effect was reversed by inhibition of the P-glycoprotein 1 transporter with ciclosporin. By contrast, non-human primate studies with either 11C-lansoprazole or 18F-lansoprazole showed unencumbered tracer entry into the brain. Human studies with these tracers have not been reported to date." generally we don't report non-human studies. We could ~potentially~ discuss this in a Research section.... but even that might be UNDUE. Jytdog (talk) 02:08, 17 May 2015 (UTC)Reply

I agree with Jytdog that primary sources should be avoided with regards to medical content (per WP:MEDRS). However, Lansoprazole is still an organic compound. While it is primarily notable for its use as a drug for proton pump inhibition(where WP:MEDRS would apply), a section regarding the molecule's notable, published properties is not subject to the same rules. For instance, use of primary sources for a hypothetical section on notable spectral properties of lansoprazole would be acceptable. As for the derivatives, [¹⁸F] N-methyl lansoprazole and [¹¹C]N-methyl lansoprazole, these are probably not notable enough to warrant their own article due to the lack of approval for use in humans (as mentioned above). However, their close relationship to lansoprazole as well as their mention in popular media and multiple reviews certainly warrants a brief comment in this article. Bcary (talk) 19:33, 17 May 2015 (UTC)Reply

if you ask the question about why you (or anybody) cares about the potential use of lansoprazole analogs as imaging agents, the question about MEDRS becomes clear. Right? btw, have you read the part of MEDRS called WP:MEDREV? it explicitly speaks to the popular media stuff. please do read it. thanks. Jytdog (talk) 20:05, 17 May 2015 (UTC)Reply

The exclusion of unambiguous, noteworthy properties of lansoprazole per MEDRS is totally unwarranted: regardless of potential medical applications. I refer here to the BBB impermeability and the high affinity interaction with tau polymers. These properties are well-demonstrated and very unlikely to be overturned by new evidence (which is, of course, the reason MEDRS exists). I suppose we could exclude the portion regarding the labeled derivatives until more information is available. However, I still support the inclusion of a brief comment. Perhaps, only referring to the derivatives as (potential) research tools. Have a look at Nifene for a similar situation. Also, the popular media source was included to bolster subject notability rather than veracity. Regards. Bcary (talk) 21:15, 17 May 2015 (UTC)Reply

would you please address the question i asked you - why does anybody care if lansoprozole can be used as an imaging agent? why are those properties worthy of note? why is the media talking about them? we can take it from there, once you answer. Thanks! Jytdog (talk) 21:49, 17 May 2015 (UTC)Reply

Those questions are irrelevant? As far as I know, there are no guidelines as to what straightforward, well-demonstrated properties aren't allowed inclusion in a notable compound's article. Bcary (talk) 23:40, 17 May 2015 (UTC)Reply

meh. you are too busy worrying about imagined consequences to have a straightforward conversation, it appears. I added a new research section on this, sourced to the Lancet review article - the only secondary source there. Jytdog (talk) 01:13, 18 May 2015 (UTC)Reply

prevacid is not allowed to be sold in canada — Preceding unsigned comment added by 65.95.193.14 (talk) 20:28, 12 May 2022 (UTC)Reply

Can you share more about this? I can't find anything about it. Penguinmlle (talk) 04:16, 13 May 2022 (UTC)Reply